These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
210 related articles for article (PubMed ID: 15140279)
1. Effects of dopamine D2 receptor Ser311Cys polymorphism and clinical factors on risperidone efficacy for positive and negative symptoms and social function. Lane HY; Lee CC; Chang YC; Lu CT; Huang CH; Chang WH Int J Neuropsychopharmacol; 2004 Dec; 7(4):461-70. PubMed ID: 15140279 [TBL] [Abstract][Full Text] [Related]
3. Association of risperidone treatment response with a polymorphism in the 5-HT(2A) receptor gene. Lane HY; Chang YC; Chiu CC; Chen ML; Hsieh MH; Chang WH Am J Psychiatry; 2002 Sep; 159(9):1593-5. PubMed ID: 12202283 [TBL] [Abstract][Full Text] [Related]
4. Risperidone-related weight gain: genetic and nongenetic predictors. Lane HY; Liu YC; Huang CL; Chang YC; Wu PL; Lu CT; Chang WH J Clin Psychopharmacol; 2006 Apr; 26(2):128-34. PubMed ID: 16633140 [TBL] [Abstract][Full Text] [Related]
5. Effects of DRD2/ANKK1 gene variations and clinical factors on aripiprazole efficacy in schizophrenic patients. Shen YC; Chen SF; Chen CH; Lin CC; Chen SJ; Chen YJ; Luu SU J Psychiatr Res; 2009 Mar; 43(6):600-6. PubMed ID: 18926547 [TBL] [Abstract][Full Text] [Related]
6. Effect of DRD2, 5-HT2A, and COMT genes on antipsychotic response to risperidone. Yamanouchi Y; Iwata N; Suzuki T; Kitajima T; Ikeda M; Ozaki N Pharmacogenomics J; 2003; 3(6):356-61. PubMed ID: 14610521 [TBL] [Abstract][Full Text] [Related]
7. Effects of patient demographics, risperidone dosage, and clinical outcome on body weight in acutely exacerbated schizophrenia. Lane HY; Chang YC; Cheng YC; Liu GC; Lin XR; Chang WH J Clin Psychiatry; 2003 Mar; 64(3):316-20. PubMed ID: 12716274 [TBL] [Abstract][Full Text] [Related]
8. Pharmacogenetic studies of response to risperidone and other newer atypical antipsychotics. Lane HY; Lee CC; Liu YC; Chang WH Pharmacogenomics; 2005 Mar; 6(2):139-49. PubMed ID: 15882132 [TBL] [Abstract][Full Text] [Related]
9. RGS4 polymorphisms predict clinical manifestations and responses to risperidone treatment in patients with schizophrenia. Lane HY; Liu YC; Huang CL; Chang YC; Wu PL; Huang CH; Tsai GE J Clin Psychopharmacol; 2008 Feb; 28(1):64-8. PubMed ID: 18204343 [TBL] [Abstract][Full Text] [Related]
10. Comparing the influence of dopamine D₂ polymorphisms and plasma drug concentrations on the clinical response to risperidone. Yasui-Furukori N; Tsuchimine S; Saito M; Nakagami T; Sugawara N; Fujii A; Kaneko S J Clin Psychopharmacol; 2011 Oct; 31(5):633-7. PubMed ID: 21869689 [TBL] [Abstract][Full Text] [Related]
11. Identification of genetic correlates of response to Risperidone: Findings of a multicentric schizophrenia study from India. Kaur G; Gupta D; Chavan BS; Sinhmar V; Prasad R; Tripathi A; Garg PD; Gupta R; Khurana H; Gautam S; Margoob MA; Aneja J Asian J Psychiatr; 2017 Oct; 29():174-182. PubMed ID: 28692863 [TBL] [Abstract][Full Text] [Related]
12. Pharmacogenetics of treatment in first-episode schizophrenia: D3 and 5-HT2C receptor polymorphisms separately associate with positive and negative symptom response. Reynolds GP; Yao Z; Zhang X; Sun J; Zhang Z Eur Neuropsychopharmacol; 2005 Mar; 15(2):143-51. PubMed ID: 15695058 [TBL] [Abstract][Full Text] [Related]
13. Dopamine (DRD2) and Serotonin (HTR2A, 2C) Receptor Gene Polymorphisms do not influence early response to Risperidone in South Indian Patients with Schizophrenia. Alladi CG; RajKumar RP; Adithan S; Marie-Claire C; Bellivier F; Shewade DG Fundam Clin Pharmacol; 2019 Jun; 33(3):355-364. PubMed ID: 30332506 [TBL] [Abstract][Full Text] [Related]
14. Risperidone response and 5-HT6 receptor gene variance: genetic association analysis with adjustment for nongenetic confounders. Lane HY; Lin CC; Huang CH; Chang YC; Hsu SK; Chang WH Schizophr Res; 2004 Mar; 67(1):63-70. PubMed ID: 14741325 [TBL] [Abstract][Full Text] [Related]
16. Randomized clinical comparison of perospirone and risperidone in patients with schizophrenia: Kansai Psychiatric Multicenter Study. Okugawa G; Kato M; Wakeno M; Koh J; Morikawa M; Matsumoto N; Shinosaki K; Yoneda H; Kishimoto T; Kinoshita T Psychiatry Clin Neurosci; 2009 Jun; 63(3):322-8. PubMed ID: 19566763 [TBL] [Abstract][Full Text] [Related]
17. Gene polymorphism influencing treatment response in psychotic patients in a naturalistic setting. Alenius M; Wadelius M; Dahl ML; Hartvig P; Lindström L; Hammarlund-Udenaes M J Psychiatr Res; 2008 Sep; 42(11):884-93. PubMed ID: 18086475 [TBL] [Abstract][Full Text] [Related]
18. ALDH2 polymorphism, associated with attenuating negative symptoms in patients with schizophrenia treated with add-on dextromethorphan. Lee SY; Chen SL; Chang YH; Chen PS; Huang SY; Tzeng NS; Wang LJ; Lee IH; Wang TY; Chen KC; Yang YK; Hong JS; Lu RB J Psychiatr Res; 2015 Oct; 69():50-6. PubMed ID: 26343594 [TBL] [Abstract][Full Text] [Related]
19. Dopamine D2 receptor gene polymorphisms predict well the response to dopamine antagonists at therapeutic dosages in patients with schizophrenia. Sakumoto N; Kondo T; Mihara K; Suzuki A; Yasui-Furukori N Psychiatry Clin Neurosci; 2007 Apr; 61(2):174-80. PubMed ID: 17362435 [TBL] [Abstract][Full Text] [Related]
20. 5-HT2A receptor gene polymorphism and negative symptoms in first episode (drug-naive) Chinese Han nationality individuals with schizophrenia. Wang YH; Li WQ; Huang Z; Shi YZ; Wang XY; Huang JS; Zhou XH; Chen HX; Hao W Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2008 Apr; 33(4):293-8. PubMed ID: 18460771 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]